Bernardo Bonanni - Genetic Mutations

Author Information

Bernardo Bonanni is affiliated with the Division of Cancer Prevention and Genetics at the European Institute of Oncology IRCCS located in Milan, Italy. His work primarily revolves around cancer genetics and prevention, focusing on genetic testing, risk modeling, and the role of diet and microbiome in cancer risk.

Research Contributions

Bernardo Bonanni has made significant contributions to the field of cancer genetics and prevention. Notable research from 2022 includes studies on psychological determinants of men's adherence to BRCA1/2 cascade screening, polygenic risk modeling for epithelial ovarian cancer, and the impact of common variants in breast cancer risk loci on tumor subtypes. His work also encompasses the benefits of aspirin in colorectal cancer prevention for Lynch Syndrome patients and the role of immune-related genes in breast cancer recurrence. In 2021, he investigated the microbiome's role as a mediator of diet on colorectal cancer risk, analyzed BRCA1/2 pathogenic variants in Northern Italy, and explored alternative dosing of exemestane in postmenopausal women with ER-positive breast cancer.

Aliases

B Bonanni, B. Bonanni, Bernardo Bonanni

Publication and Citation Metrics

Metric	Value
H-Index	67
Citation Count	17541
Paper Count	432

Publications:

Psychological Determinants of Men’s Adherence to Cascade Screening for BRCA1/2

DOI: 10.3390/curroncol29040203

Year: 2022

Correction: Polygenic risk modeling for prediction of epithelial ovarian cancer risk.

DOI: 10.1038/s41431-022-01085-y

Year: 2022

A randomized controlled trial comparing self-referred message to family-referred message promoting men’s adherence to evidence-based guidelines on BRCA1/2 germline genetic testing: A registered study protocol

DOI: 10.1371/journal.pone.0266327

Year: 2022

Common variants in breast cancer risk loci predispose to distinct tumor subtypes

DOI: 10.1186/s13058-021-01484-x

Year: 2022

Aspirin Colorectal Cancer Prevention in Lynch Syndrome: Recommendations in the Era of Precision Medicine

DOI: 10.3390/genes13030460

Year: 2022

Polygenic risk modeling for prediction of epithelial ovarian cancer risk

DOI: 10.1038/s41431-021-00987-7

Year: 2022

Abstract P1-22-03: Expression of immune-related genes and breast cancer recurrence in women with ductal carcinoma in situ

DOI: 10.1158/1538-7445.sabcs21-p1-22-03

Year: 2022

Microbiome as Mediator of Diet on Colorectal Cancer Risk: The Role of Vitamin D, Markers of Inflammation and Adipokines

DOI: 10.3390/nu13020363

Year: 2021

Analysis of Italian BRCA1/2 Pathogenic Variants Identifies a Private Spectrum in the Population from the Bergamo Province in Northern Italy

DOI: 10.3390/cancers13030532

Year: 2021

Alternative dosing of exemestane in postmenopausal women with ER-positive breast cancer. Design and methods of a randomized presurgical trial

DOI: 10.1016/j.cct.2021.106498

Year: 2021

How Do Genetic Mutations Influence ASD?

What is Third Generation Sequencing?

What Types of Immunotherapy Are Available?

What is the Evolutionary Significance of Gene Amplification?

What Are the Alternatives to Hydroxyurea?

What are PARP Inhibitors?

How is the Delta F508 Mutation Diagnosed?

What are Genetic Duplications?

Can Nucleotide Mutations Be Repaired?

What Are Some Diseases Caused by Nucleotide Mutations?

Partnered Content Networks

Relevant Topics